NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
Summary
The warrants have a term of five years from the date of issuance and an exercise price of $0.75 per share.The private placement is subject to customary closing conditions and is expected to close during the week of August 12, 2014.Insiders, including senior management of NeuroSense, the Chief Executive Officer, the Chief Financial Officer, the Chief Medical Officer, and members of the CEOs family, as well as previously existing shareholders, are participating in the offering.Proceeds from the private placement are expected to be used for general corporate and working capital purposes.Alon Ben-Noon, NeuroSenses CEO, commented: "Our senior management team are highly confident and enthusiastic about PrimeCs potential, especially given the positive results from our Phase 2b PARADIGM Study. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSenses strategy is to develop combined therapies targeting multiple pathways associated with these diseases.For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. These risks include unexpected R&D costs or operating expenses, a delay in the reporting of additional results from PARADIGM clinical trial, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSenses filings with the Securities and Exchange Commission (SEC). Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.